This study determined the overall incidence of postoperative nausea and vomiting (PONV) in 38 patients undergoing laparoscopic gynaecological procedures who received a standardized propofol/isoflurane anaesthetic but no preoperative antiemetic. A further 166 patients similarly anaesthetized were then randomly allocated to receive either metoclopramide 10 mg, ondansetron 4 mg, or cyclizine 50 mg as an intravenous antiemetic immediately preinduction. Overall incidence of PONV was determined for all groups and the relative efficacy of the three antiemetic agents assessed.
Postoperative nausea and vomiting (PONV) is a distressing side-effect of many laparoscopic procedures, with incidence variously reported as between 30 and 70% [1] [2] [3] . Severe PONV can result in delayed discharge from day-case units, overnight admission and diminished patient satisfaction. Various factors (patient age, history of motion sickness, phase of menstrual cycle, use of opiates) have been associated with higher incidences of PONV in laparoscopic surgery [4] [5] [6] . The pathogenesis of PONV involves a combination of patient, surgical and anaesthetic factors. The anaesthetist, with modification of perioperative management, can control only the latter. Avoidance of anxiety and hypotension, adequate starvation and minimization of mechanical stimuli to the gastrointestinal tract have all been recommended 2, 5, 6 .
Pharmacological agents implicated as emetogenic include opiates, barbiturates, volatile anaesthetic agents, nitrous oxide and neostigmine. The evidence in some cases, particularly with respect to neostigmine, is contradictory at present 7, 8 . Administration of intravenous fluids has however been clearly associated with improvements in morbidity in day case surgery 4 . In addition a wide range of antiemetics are being currently employed in anaesthetic practice in an attempt to minimize the incidence of PONV, with most acting as antagonists at various receptors in the chemoreceptor trigger zone (CTZ). Antiemetics in common use in anaesthetic practice include droperidol, prochlorperazine, metoclopramide, cyclizine and the more recently developed agent, ondansetron. Droperidol has some potentially undesirable sedative properties which may interfere with its use in therapeutic doses in the day-case setting, and was not commonly favoured by the anaesthetists contributing to this study. Prochlorperazine is not licensed for intravenous use in New Zealand. In this study we therefore concentrated on the latter three agents. Metoclopramide is a dopamine (DI) receptor antagonist and is widely used in the prophy-laxis and treatment of PONV. It has few sedative properties at low dose but is associated with occasional extrapyramidal side-effects. Other desirable properties are an increase in lower oesophageal sphincter tone and accelerated gastric emptying. Cyclizine is a piperazine derivative anti-histamine and also possesses some anti-muscarinic properties.
In some early studies its use has been associated with satisfactory relief of nausea in up to 77% of patients 9 .
Comparatively little however, has been reported of either its pharmacokinetics or its efficacy despite fairly widespread use in general medicine, prenatal obstetrics and anaesthesia. It is included in this study as it is part of this hospital's standing-order regimen for management of nausea and vomiting.
Ondansetron is a new-generation selective 5-hydroxytryptamine (5-HT 3 ) receptor antagonist acting both centrally and at receptors in the gastrointestinal tract. It has proven efficacy in the prevention and treatment of nausea associated with chemotherapy 10 . Ondansetron is also unique in having no reported clinically significant side-effects, and is currently being actively promoted as the optimum antiemetic for use in day-case surgery. Previous studies have demonstrated clear superiority in favour of ondansetron when compared with both metoclopramide and placebo [11] [12] [13] [14] . A 4 mg dose of ondansetron has been shown to be optimally effective 15, 16 . There are no studies comparing ondansetron and cyclizine directly.
Only one of the above studies 11 utilized a propofol induction and some permitted wide variations in the remainder of the anaesthetic technique. Propofol is the preferred induction agent for day-case surgery in our unit on the basis of its smooth induction and rapid emergence properties, but recent evidence has also shown it to possess intrinsic antiemetic properties [17] [18] [19] . Some variation in the incidence of PONV may therefore be predicted to occur when this agent is used for anaesthesia. This study was designed to assess the incidence of nausea and vomiting following gynaecological laparoscopy in patients receiving a propofol induction standardized anaesthetic, and to compare the relative efficacy of metoclopramide, ondansetron and cyclizine as prophylactic antiemetics in this population.
PATIENTS AND METHODS
Following local Ethical Committee approval and with informed patient consent, women who were presenting for elective laparoscopic procedures on a daystay basis over a nine-month period were enrolled in the study. Any patient who was pregnant, who had taken any opiate or antiemetic in the preceding 24 hours or who had a history of hypersensitivity to any of the trial agents was excluded. Patients who on assessment were deemed to be better served by an anaesthetic different from the standard technique (obesity, reflux, difficult airway) were also excluded.
This study was conducted in two phases. An initial pilot study (comprising 38 patients) assessed the incidence of PONV in a population receiving the standard anaesthetic in the absence of a prophylactic antiemetic, and was to determine the power required for the comparative study. The second phase was a randomized, double-blind comparison of the efficacy of the three study antiemetics. All test agents were supplied to the administering anaesthetist in capped and coded syringes containing 2 ml of colourless liquid.
All patients received a standard anaesthetic beginning with a temazepam premedication (10 mg if weight <60 kg, 20 mg if weight >60 kg). All phase two patients also received the test antiemetic immediately following cannula insertion. They were then observed for any side-effects. Anaesthesia was induced in all patients with fentanyl 1.5 µg/kg and propofol 2 to 3 mg/kg to loss of response to verbal command. Muscle relaxation was attained with vecuronium 0.08 mg/kg. All patients were intubated and the lungs ventilated to normocapnia for the duration of the procedure. Maintenance was with 50% nitrous oxide in oxygen supplemented by isoflurane 0.5-1.0%. Neuromuscular block was monitored with a peripheral nerve stimulator and reversed as appropriate with atropine and neostigmine. All patients received diclofenac 100 mg PR and 1 litre of Hartmann's solution perioperatively. All operative procedures were performed by the same group of gynaecologists with duration being 20 to 30 minutes routinely. Patients requiring more extensive procedures were not included in this study. Supplemental analgesia was provided by morphine intravenously according to standard nursing protocols on a p.r.n. basis while in the recovery room, and morphine 10 mg IM as required once back on the ward. Prochlorperazine 12.5 mg IM was the recommended rescue antiemetic.
Nausea was assessed on a four-point scale: 0 absence of PONV, 1 mild nausea settling spontaneously, 2 nausea requiring treatment, 3 actual emetic episode.
Assessment was made in the recovery room two 547 ANTIEMETICS FOR DAY-CASE LAPAROSCOPY hours postoperatively and at time of discharge from the day-stay unit (usually four to six hours post operation), by the attending nursing staff. Scores at 24 hours were attained by phone or standard questionnaire via return mail by the investigator. The degree of sedation was assessed on a similar four-point scale and recorded at the same time intervals. Data on administration of opiates (total dose received) and rescue antiemetics were collected from the case records on the day following surgery. At the conclusion of the study the trial drug code was broken and patients separated into three groups according to the antiemetic they had received. Patients enrolled in the Phase 1 pilot study were analyzed separately.
Overall incidence of PONV was determined by isolating patients with a nausea score of 2 or greater at any time (clinically significant PONV) and this was expressed as a percentage of the group as a whole. This data was tested using Chi-square analysis. The Phase 2 antiemetic groups were compared on all nausea and sedation scores using Kruskal-Wallis oneway analysis of variance. The relationship between day of menstrual cycle and postoperative nausea and vomiting was tested using the Spearman Rank Correlation. Significance level for all tests was set at P<0.05. All statistical analysis was performed utilizing the NCSS statistical package (Kaysville, Utah).
RESULTS
A total of 209 patients were enrolled in the study. Five patients were subsequently excluded from the data analysis; four because they could not be traced at 24 hours and one because of absence of drug code on the data collection form.
The first 38 patients comprised those involved in the phase one incidence study, with a further 166 making up the comparative trial population. Of the patients in the comparative trial, 54 were given metoclopramide (Group M), 59 received ondansetron (Group O) and 53 cyclizine (Group C).
Phase 1 Incidence Study
Thirty-eight patients were included in this portion of the study with each receiving the standard anaesthetic with an antiemetic administered only on a p.r.n. basis post-procedure. This study population was divided at time of analysis into two sub-groups; those with a nausea score of 2 or more at any time (n=18) and those who consistently scored 1 or 0 indicating minimal PONV morbidity (n=20). These sub-groups are referred to as Group A and Group B respectively in Table 1 .
The two sub-groups were comparable with respect to demographic data in opiate usage, with only past history of PONV being significantly correlated with current PONV (P=0.01). Overall incidence of PONV was 48%. There was a 9% overnight admission rate as a result of severe nausea or unrelenting emesis.
The incidence result was used to determine the power necessary for the comparative trial, and showed that a sample of 160 patients would be sufficient to detect differences in efficacy between three agents with 95% confidence.
Phase 2 Comparative Trial
A total of 166 patients took part in the comparative drug trial phase. Demographic data ( similar in the three groups for mean patient age, day of menstrual cycle and type of operation. Distribution of patients with a past history of motion sickness or previous PONV was comparable between groups and likewise there was no difference of significance in the distribution of operative procedures. The PONV scores were similar for all three groups when assessed in the recovery room and at 24 hours postoperatively. There were, however, significantly lower PONV scores in Groups M and O at both 2 hours (P=0.008) and at discharge (P=0.002) when compared with Group C. There were no significant differences in the PONV scores between Groups M and O when analyzed separately (P>0.5 for all assessment intervals).
Opiate usage was similar for all groups with overall mean usage being 8.8 mg (SEM 0.62) per patient. Forty-nine patients (30%) in the Phase 2 trial suffered clinical nausea or vomiting as defined by a PONV score of 2 or greater at any time. Thirteen of these patients were in Group M (24%), 12 in Group O (20%) and 27 in Group C (50.9%). There was no correlation between day of menstrual cycle and development of PONV (P=0.89). No dystonic sideeffects or major adverse reactions were recorded for any of the trial agents. Thirteen patients (10 in Group M, 2 in Group O, and 1 in Group C) reported transient arm pain on injection of the trial drug, and one patient who received cyclizine developed localized erythematous rash. Six patients out of the 166 who had received a trial antiemetic (3.6%) required hospital admission as a result of severe nausea and/or vomiting. Two of these patients were in group O and four in Group C. No patient from Group M required admission overnight as a result of PONV (Table 4 ). This contrasts with four out of 38 patients (9%) in the Phase 1 trial.
DISCUSSION
It has been postulated that an antiemetic is not required routinely for laparoscopic procedures 20,21 . Hitchcock and Ogg contest that attention to other perioperative factors such as avoidance of neostigmine and opiates can in combination reduce the incidence of PONV and obviate the need for routine antiemetics. This study demonstrates that postoperative nausea and vomiting remains a significant complication in patients undergoing laparoscopic gynaecological procedures given the anaesthetic regimen adopted for the purposes of this study. Fifty per cent of patients in the Phase 1 trial reported distressing PONV despite utilizing a propofol induction technique, restricting opiate usage and administering perioperative fluids. That this incidence could be halved with intravenous administration of either metoclopramide 10 mg or ondansetron 4 mg prior to induction was demonstrated in the Phase 2 study. Administration of cyclizine 50 mg had little effect on the incidence of PONV in the same population. This study demonstrated minimal differences in antiemetic efficacy between ondansetron and metoclopramide when administered as above. Both agents were significantly more effective antiemetics when assessed at two hours postoperatively and at the time of discharge, than cyclizine. That ondansetron is an effective prophylactic antiemetic has been demonstrated previously 12, 13, 16 , and in addition previous comparative studies had shown it to be a clearly superior agent to metoclopramide 11, 14 . The results of Malins et al 11 demonstrating ondansetron's superiority when a similar anaesthetic drug regimen was used were not reproduced in this study. This may be related to differences in the route of administration of metoclopramide (10 mg orally with premedication as in previous studies versus 10 mg intravenously at induction in this study), resulting in different peak serum levels. 549 
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Anaesthesia and Intensive Care, Vol. 24, No. 5, October 1996 Having established that prophylactic intravenous administration of either ondansetron or metoclopramide can significantly decrease the incidence of PONV, it was reassuring to confirm the absence of major side-effects with these agents. Both metoclopramide and cyclizine have been historically implicated in production of drowsiness in high doses 13, 24 however, this study failed to demonstrate any difference between any of the agents following analysis of sedation scores. Of interest was the 17% incidence of pain on injection with metoclopramide. The pain was transient and only occurred when the drug was administered as the first agent through the IV cannula. This phenomena has been previously described by Wilkinson 25 and can possibly be alleviated by flushing of the new cannula with saline following insertion.
The concepts of continuous quality improvement (CQI) are of increasing importance in modern daystay anaesthesia. Encompassed within this is the need for cost-effective drug utilization 26 . The overnight admission rate as a result of nausea and vomiting in the Phase 1 study (no antiemetics) was almost 10% which was reduced to 3.6% when a prophylactic antiemetic was administered. If those patients who received the minimally effective cyclizine prophylaxis are excluded, the admission rate drops to 1.8%. Thus the costs associated with additional drug utilization can be balanced against obvious savings in bed occupancy. Ondansetron 4 mg ($NZ30.32) is considerably more expensive than metoclopramide 10 mg ($NZ0.84), and routine use of ondansetron for all patients may not be justified. Taking into account the results of this study the routine use of metoclopramide prophylaxis for patients undergoing gynaecological laparoscopy is supported. Metoclopramide appears an effective agent when a propofol induction anaesthetic technique is employed. The possibility of an additive antiemetic effect between the two agents remains to be fully explored. Ondansetron, however, has been shown in a number of studies to be effective not only in the prophylaxis of PONV but also in the treatment of established nausea and vomiting 12, 15 . Reserving this agent then for patients who develop nausea and vomiting despite metoclopramide prophylaxis may further reduce post-laparoscopy morbidity and minimize overnight hospital admission.
We conclude that the incidence of postoperative nausea and vomiting following gynaecological laparoscopic surgery can be reduced by utilization of metoclopramide 10 mg or ondansetron 4 mg intravenously prior to propofol induction. Both agents were clearly superior to cyclizine 50 mg, and may potentially decrease postoperative nausea and vomiting by around 50% when contrasted with an historical group of patients similarly anaesthetized, but in whom prophylactic antiemetics were withheld. Metoclopramide is the more cost-effective agent in the scenario, with ondansetron possibly being reserved as the rescue agent of choice or as first-line prophylaxis in patients historically unresponsive to metoclopramide.
